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nonvascular death, macrovascular complications and microvascular complications. Macrovascular complications included nonfatal stroke, fatal stroke, total stroke, angina, nonfatal myocardial infarction (MI), fatal MI, sudden death, total coronary hearth disease (CHD), and total macrovascular complications. Corrections were calculated for the base risks for MI, stroke, all-cause mortality and microvascular disease among obese patients with arterial hypertension. They were also calculated for nonfatal and fatal MI for obese patients with both arterial hypertension and hypercholesterolaemia. These outcomes were included in the model as input parameters.
The effect on mortality and micro-and macrovascular complications of treating patients with orlistat was assessed in two steps: the effect of weight loss with orlistat on the risk factors, and the effect of risk factors on morbidity and mortality.
Study designs and other criteria for inclusion in the review
The authors did not report any criteria for including studies in the review. The majority of the effectiveness data were derived from a randomised double-blind study, although the results were combined with data derived from other studies such as prospective observational studies.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
At least nine published studies of several types were included in the review. These included a randomised double-blind study and two prospective observational studies. These studies were published between 1992 and 2000.
Methods of combining primary studies
The majority of the effectiveness data were collected from the randomised double-blind study. These were with the results of the other included studies using a narrative method.
Investigation of differences between primary studies
Not reported.
Results of the review
The base rates (without orlistat) in obese patients, free of events and without hypertension and hypercholesterolaemia, were as follows: For obese diabetic patients with hypercholesterolaemia, the same base risks for fatal and nonfatal MI as for patients without hypercholesterolaemia and given no orlistat treatment, were applied.
Measure of benefits used in the economic analysis
The measures of benefits used were the life-years gained (LYG) and the estimated mortality rate for the 10-year study period.
Direct costs
The direct costs included in the cost analysis were the total health care costs per year for patients without complications (1,726 euros), with microvascular complications (2,578 euros), with macrovascular complications (3,844 euros), and with both micro-and macrovascular complications (5,443 euros). The resource quantities and the unit costs were not reported separately. These costs were included in the Markov model to extrapolate the costs for the 10-year period considered in the study. The costs were estimated from one published study. Discounting of the costs was carried out in the sensitivity analysis using a 3% discount rate. As the costs were incurred over a 10-year period, discounting would have been relevant for the base-case analysis. The costs reported were the average and incremental costs. The costs were reported for the year 1998 and were adapted to year 2000 using a 3% inflation rate.
Statistical analysis of costs
No statistical analysis of the costs was reported.
Indirect Costs
The indirect costs were not reported.
Currency
Euros.
Sensitivity analysis
Sensitivity analyses were carried out to analyse variability in data when: discounting of the costs was performed at a discounting rate of 3%;
the effects of orlistat on the risk of events were increased and decreased in one standard deviation for obese diabetic patients without arterial hypertension and without hypercholesterolaemia, and for obese diabetic patients with arterial hypertension and with hypercholesterolaemia; and the catch-up period for recovering the weight lost was reduced to 2.5 years.
Estimated benefits used in the economic analysis
The authors reported the incremental benefits in terms of the number of LYG with orlistat, compared with placebo.
For obese diabetic patients without arterial hypertension and without hypercholesterolaemia at the beginning of the study, orlistat increased the number of LYG by 0.08 when compared with placebo.
For obese diabetic patients with arterial hypertension and without hypercholesterolaemia at the beginning of the study, there was an increase of 0.204 LYG with orlistat when compared with placebo.
For patients with hypercholesterolaemia but without arterial hypertension at the beginning of the study, the number of LYG was 0.227 with orlistat when compared with placebo.
Finally, among patients with arterial hypertension and hypercholesterolaemia, orlistat increased the number of LYG by 1.641 when compared with placebo.
The estimated mortality rate over the 10-year study period was 11.7% in the orlistat group, compared with 12.7% in the control group. 
Cost results
When obese diabetic patients were not treated with orlistat, the cost for a patient without arterial hypertension and without hypercholesterolaemia at the beginning of the study was 15,573 euros;
the cost for a patient with hypercholesterolaemia but without arterial hypertension was 15,741 euros;
the cost for a patient with arterial hypertension and without hypercholesterolaemia was 15,450 euros; and the cost for a patient with hypercholesterolaemia and arterial hypertension was 15,444 euros.
When obese diabetic patients were treated with orlistat, the cost per patient was 17,180 euros for those who did not have hypercholesterolaemia or arterial hypertension at the beginning of the study;
17,255 euros for those with hypercholesterolaemia and without arterial hypertension at the beginning of the study;
17,128 euros for those with arterial hypertension and without hypercholesterolaemia at the beginning of the study; and 17,085 euros for those with both hypercholesterolaemia and arterial hypertension at the beginning of the study.
Among diabetic patients without hypercholesterolaemia and arterial hypertension at the beginning of the study, the incremental cost of being treated with orlistat when compared with no treatment was 1,608 euros. The difference was 1,514 euros for those patients with hypercholesterolaemia and without arterial hypertension at the beginning of the study. The difference was 1,678 euros for those with arterial hypertension but without hypercholesterolaemia, and 1,641 for those with both hypercholesterolaemia and arterial hypertension.
Synthesis of costs and benefits
The incremental cost-effectiveness ratio was calculated as the incremental cost of orlistat when compared with no treatment, divided by the corresponding incremental benefits.
For obese diabetic patients without hypercholesterolaemia and arterial hypertension at the beginning of the study, the cost per LYG when treated with orlistat in comparison with placebo was 19,986 euros. The cost-effectiveness ratio was 7,407 euros for those patients with hypercholesterolaemia and without arterial hypertension at the beginning of the study. The cost-effectiveness ratio was 7,388 euros for those with arterial hypertension but without hypercholesterolaemia, and 3,462 euros for those with both hypercholesterolaemia and arterial hypertension.
Sensitivity analyses showed that the cost-effectiveness ratio for patients without hypertension or hypercholesterolaemia at the beginning of the study increased considerably when the costs were discounted, and when the effects of orlistat on the events were decreased. For patients with hypertension and/or hypercholesterolaemia, the sensitivity analysis showed the robustness of the cost-effectiveness ratios.
